No Data
No Data
Northland Securities Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $12
Northland Says MiMedx 'Oversold,' Sees 'Compelling Buying Opportunity'
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences
Parker H. "Pete" Petit Issues Numerous Warnings to Business Leaders in The Second Edition of His Book: The Entrepreneur's Dilemma: The Weaponization and Politicization of Our Justice System
Recent 5.0% Pullback Isn't Enough to Hurt Long-term MiMedx Group (NASDAQ:MDXG) Shareholders, They're Still up 136% Over 5 Years
MiMedx Group, Inc.'s (NASDAQ:MDXG) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?